These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7914053)

  • 1. Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride.
    Lewander T
    Acta Psychiatr Scand Suppl; 1994; 380():64-7. PubMed ID: 7914053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs.
    Lindström LH
    Acta Psychiatr Scand Suppl; 1994; 380():74-6. PubMed ID: 7914054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
    Lapierre YD; Ancill R; Awad G; Bakish D; Beaudry P; Bloom D; Chandrasena R; Das M; Durand C; Elliott D
    J Psychiatry Neurosci; 1992 Oct; 17(4):134-45. PubMed ID: 1450186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptics and the neuroleptic-induced deficit syndrome.
    Lewander T
    Acta Psychiatr Scand Suppl; 1994; 380():8-13. PubMed ID: 7914056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
    Kerwin RW
    Br J Psychiatry; 1994 Feb; 164(2):141-8. PubMed ID: 7513599
    [No Abstract]   [Full Text] [Related]  

  • 6. [Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses].
    Lewander T; Westerberg SE; Ogren SO; Von Bahr C; Köhler C
    Encephale; 1990; 16(2):153-7. PubMed ID: 1972054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antipsychotics in schizophrenia: the French experience.
    Vanelle JM; Olié JP; Lévy-Soussan P
    Acta Psychiatr Scand Suppl; 1994; 380():59-63. PubMed ID: 7914051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia.
    Klieser E; Strauss WH; Lemmer W
    Acta Psychiatr Scand Suppl; 1994; 380():68-73. PubMed ID: 8048341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.
    Lapierre YD; Nair NP; Chouinard G; Awad AG; Saxena B; Jones B; McClure DJ; Bakish D; Max P; Manchanda R
    Acta Psychiatr Scand Suppl; 1990; 358():72-7. PubMed ID: 1978496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of neuroleptics on cognitive and psychomotor function.
    King DJ
    Br J Psychiatry; 1990 Dec; 157():799-811. PubMed ID: 1981157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
    Deo R; Soni S; Rastogi SC; Levine S; Plant I; Edwards JG; Mitchell M; Chanas A
    Acta Psychiatr Scand Suppl; 1990; 358():120-4. PubMed ID: 1978470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
    Chouinard G
    J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor impairment and cognitive disturbances induced by neuroleptics.
    King DJ
    Acta Psychiatr Scand Suppl; 1994; 380():53-8. PubMed ID: 7914050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.
    Ahlfors UG; Rimön R; Appelberg B; Hagert U; Harma P; Katila H; Mahlanen A; Mehtonen OP; Naukkarinen H; Outakoski J
    Acta Psychiatr Scand Suppl; 1990; 358():99-103. PubMed ID: 1978501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New psychopharmacologic alternatives in treatment of schizophrenia].
    Bryois C
    Schweiz Arch Neurol Psychiatr (1985); 1994; 145(6):19-24. PubMed ID: 7533941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remoxipride in schizophrenia: effects on plasma prolactin.
    Chouinard G; Turnier L; Kallai-Sanfacon MA
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):599-603. PubMed ID: 2868493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
    Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
    Lindström LH; Wieselgren IM; Struwe G; Kristjansson E; Akselson S; Arthur H; Andersen T; Lindgren S; Norman O; Naimell L
    Acta Psychiatr Scand Suppl; 1990; 358():130-5. PubMed ID: 1978472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences of long-term treatment with remoxipride: efficacy and tolerability.
    Wålinder J; Holm AC
    Acta Psychiatr Scand Suppl; 1990; 358():158-63. PubMed ID: 1978477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.
    Wadworth AN; Heel RC
    Drugs; 1990 Dec; 40(6):863-79. PubMed ID: 1981869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.